InsidersTradesSigma
Track the SCHOTT Pharma AG & Co. KGaA stock price and the full insider trade history of the company, a listed equity based in Germany. Shares trade on the DE market, under the oversight of BaFin. Operating in the Healthcare & Pharma sector, SCHOTT Pharma AG & Co. KGaA has published 4 insider filings. Market capitalisation: €3.3bn. The latest transaction was disclosed on 13 February 2026 (Buy). Among the most active insiders: Mayer, Reinhard. Every trade is accessible without an account.
4
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate SCHOTT Pharma AG & Co. KGaA Buy (bullish), based on 12 analysts. Average price target: €20.48.
15Σ signal
Fundamental score
Ranked 8,351 of 29,064 companies
62.1
score / 100
Value52
Quality72
FCF yld1.1%
Earn yld4.5%
EV/EBITDA11.7x
ROE15%
Gross mgn34%
Net mgn15%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 February 2026
Declarations4 total
3,350.198 shares@ €15.1236.1% of flowShareXetraISIN DE000A3ENQ51BAFIN:40034325-aeae05223ebe
6,998.67 shares@ €15.73100.0% of flowShareXetraISIN DE000A3ENQ51BAFIN:40034325-b0487163ba29
2,999.236 shares@ €14.9331.9% of flowShareXetraISIN DE000A3ENQ51BAFIN:40034325-0df550fe3140
2,999.236 shares@ €14.9331.9% of flowShareXetraISIN DE000A3ENQ51BAFIN:40034325
4 of 4 declarations
关于 SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA 是注射药物容器解决方案和输送系统的领先供应商。该公司在德国Xetra/法兰克福（DAX/MDAX/SDAX）上市，通过其产品组合在医药包装价值链中占据强势地位，产品组合包括预充式注射器、卡式瓶、西林瓶、安瓿瓶以及相关的分析、开发、灌装和法规服务。SCHOTT Pharma 将自己定位为制药公司、生物技术公司和CDMO的端到端合作伙伴，提供I型硼硅玻璃和先进的医药聚合物解决方案。（[schott-pharma.com](https://www.schott-pharma.com/?utm_source=openai)） 该公司的历史根植于更广泛的SCHOTT集团，该集团可追溯到130多年前的Otto Schott及其在特种玻璃方面的突破。SCHOTT Pharma 于2022年成立为独立业务，旨在加速增长并增强其在资本市场的形象。其公司总部位于德国美因茨，工业足迹遍布全球，在欧洲、北美、南美和亚洲设有16个符合GMP标准的生产基地。该公司表示，其在全球拥有约4,700名员工，尽管专注于专业领域，但仍拥有庞大的国际平台。（[schott-pharma.com](https://www.schott-pharma.com/en/about-us?utm_source=openai)） 从竞争角度来看，SCHOTT Pharma 受益于其在市场中的技术领先声誉，该市场受到长期结构性需求驱动因素的支持：生物制剂、GLP-1疗法、ADC以及冷链和家庭给药形式的日益普及。该公司强调其拥有超过1,700家客户，其中包括许多世界领先的制药制造商，并强调其拥有市场上最广泛的产品系列之一。一个核心战略支柱是扩大高利润的“高价值解决方案”，这已持续提高了其对收入和盈利能力的贡献。（[schott-pharma.com](https://www.schott-pharma.com/en/news-and-media/media-releases/2022/schott-establishes-stand-alone-company-for-pharma-business-to-promote-further-growth?utm_source=openai)） 近期发展强化了其作为增长和利润故事的投资案例。在2025财年，SCHOTT Pharma 报告了稳健的季度业绩，随后实现了986.2百万欧元的全年收入，EBITDA利润率为28.4%，而高价值解决方案的份额上升至57%。管理层还指导2026财年收入在固定汇率下增长2%至5%，EBITDA利润率约为27%。2025年的治理更新包括延长首席执行官Andreas Reisse的合同以及任命Reinhard Mayer为首席财务官，这表明战略的连续性而非中断。（[schott-pharma.com](https://www.schott-pharma.com/en-gr/home/news-and-media/media-releases/2025/schott-pharma-delivers-on-full-year-revenue-and-profitability-targets?utm_source=openai)）
